The Role of Adjuvant Treatment in Patients with High-Grade Meningioma.
10.3340/jkns.2016.1111.009
- Author:
Minjae CHO
1
;
Jin Deok JOO
;
In Ah KIM
;
Jung Ho HAN
;
Chang Wan OH
;
Chae Yong KIM
Author Information
1. Department of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. chaeyong@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Meningioma;
Adjuvant radiotherapy;
Radiosurgery
- MeSH:
Diagnosis;
Follow-Up Studies;
Hand;
Humans;
Logistic Models;
Meningioma*;
Radiosurgery;
Radiotherapy;
Radiotherapy, Adjuvant;
Recurrence;
Retrospective Studies;
World Health Organization
- From:Journal of Korean Neurosurgical Society
2017;60(5):527-533
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To investigate the efficacy of adjuvant treatment in patients with high-grade meningioma. METHODS: A retrospective analysis was performed for patients with high-grade meningioma, World Health Organization grade 2 or 3, in a single center between 2003 and 2014. The patients were reviewed according to age at diagnosis, sex, the location of meningioma, degree of tumor resection, histological features, and type of adjuvant treatment. These factors were analyzed by Firth logistic regression analyses. RESULTS: Fifty-three patients with high-grade meningioma were enrolled. Thirty-four patients received adjuvant treatment; conventional radiotherapy or radiosurgery. Clinical follow-up ranged from 13–113 months with a median follow-up of 35.5 months. Gross total removal (GTR), Simpson grade 1 or 2, was achieved in 29 patients and, among them, 13 patients received adjuvant treatment. In the other 24 patients with non-GTR, conventional adjuvant radiotherapy and radiosurgery were performed in 11 and 10 patients, respectively. The other 3 patients did not receive any adjuvant treatment. Radiation-related complications did not occur. Of the 53 patients, 19 patients had suffered from recurrence. The recurrence rate in the adjuvant treatment group was 23.5% (8 out of 34). On the other hand, the rate for the non-adjuvant treatment group was 57.9% (11 out of 19) (odds ratio [OR]=0.208, p=0.017). In the GTR group, the recurrence rate was 7.5% (1 out of 13) for patients with adjuvant treatment and 50% (8 out of 16) for patients without adjuvant treatment (OR=0.121, p=0.04). CONCLUSION: Adjuvant treatment appears to be safe and effective, and could lead to a lower recurrence rate in high-grade meningioma, regardless of the extent of removal. Our results might be used as a reference for making decisions when planning adjuvant treatments for patients with high-grade meningioma after surgery.
